– Investigational oral MET inhibitor has previously received SAKIGAKE ‘fast-track’ regulatory designation in Japan – MET exon 14 skipping alterations and MET amplifications are present in 3-5% of non-small …
source https://finance.yahoo.com/news/merck-announces-fda-breakthrough-therapy-063000846.html?.tsrc=rss
blaineonline.finance.blog 